$57.69
+0.15
(+0.26%)▲
0.36%
Downside
Day's Volatility :3.36%
Upside
3.0%
77.9%
Downside
52 Weeks Volatility :81.03%
Upside
14.16%
Period | Praxis Precision Medicines I | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 5.0% | 6.5% | 0.0% |
6 Months | 53.64% | 7.1% | 0.0% |
1 Year | 313.54% | 9.8% | 0.0% |
3 Years | -76.52% | 14.2% | -20.2% |
Market Capitalization | 977.0M |
Book Value | $17.32 |
Earnings Per Share (EPS) | -10.95 |
Wall Street Target Price | 140.38 |
Profit Margin | 0.0% |
Operating Margin TTM | -9718.33% |
Return On Assets TTM | -46.65% |
Return On Equity TTM | -85.25% |
Revenue TTM | 2.2M |
Revenue Per Share TTM | 0.24 |
Quarterly Revenue Growth YOY | -36.9% |
Gross Profit TTM | 0.0 |
EBITDA | -129.7M |
Diluted Eps TTM | -10.95 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -9.94 |
EPS Estimate Next Year | -9.53 |
EPS Estimate Current Quarter | -2.08 |
EPS Estimate Next Quarter | -2.2 |
What analysts predicted
Upside of 143.34%
Sell
Neutral
Buy
Praxis Precision Medicines I is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Praxis Precision Medicines I | 42.18% | 53.64% | 313.54% | -76.52% | -86.2% |
![]() Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
![]() Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
![]() Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
![]() Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Praxis Precision Medicines I | NA | NA | NA | -9.94 | -0.85 | -0.47 | NA | 17.32 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
![]() Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
![]() Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
![]() Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Praxis Precision Medicines I | Buy | $977.0M | -86.2% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
![]() Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Praxis Precision Medicines I
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 263.0%
Adage Capital Partners Gp LLC
Cormorant Asset Management, LLC
Point72 Asset Management, L.P.
RA Capital Management, LLC
Perceptive Advisors LLC
Vanguard Group Inc
praxis precision medicines, inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. its lead product candidates include prax-114, an extrasynaptic-preferring gabaa receptor positive allosteric modulator that is in phase iia clinical trial for the treatment of major depressive disorder and perimenopausal depression; and prax-944, a selective small molecule inhibitor of t-type calcium channels, which is in phase iia clinical trial for the treatment of essential tremor. the company is also developing prax-562, a persistent sodium current blocker that is in phase i clinical trial to treat severe pediatric epilepsy and adult cephalgia; prax-222, an antisense oligonucleotide for patients with gain-of-function (gof) scn2a epilepsy; and kcnt1 program for the treatment of kcnt1 gof epilepsy. it has a cooperation and license agreement with rogcon inc.; a license agreement purdue neuroscience company; and a res
Organization | Praxis Precision Medicines I |
Employees | 82 |
CEO | Mr. Marcio Silva De'Souza M.B.A. |
Industry | Health Technology |
A Spac I Acquisition Corp
$57.69
+0.26%
Keyarch Acquisition Corp
$57.69
+0.26%
Connexa Sports Technologies Inc
$57.69
+0.26%
Us Value Etf
$57.69
+0.26%
First Wave Biopharma Inc
$57.69
+0.26%
Global X Msci Next Emerging
$57.69
+0.26%
Fat Projects Acquisition Corp
$57.69
+0.26%
Capital Link Global Fintech
$57.69
+0.26%
Applied Uv Inc
$57.69
+0.26%